Literature DB >> 8075054

Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC).

R Wierzbicki1, A Ezzat, A Abdel-Warith, A Ayoub, I Kagevi, M Fadda, J Sieck, M Abdulkareem, T Amin, A Yazigi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8075054     DOI： 10.1093/oxfordjournals.annonc.a058882

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

Review 1.  Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues.

Authors:  J D Hainsworth
Journal:  Drugs       Date:  1999       Impact factor: 9.546

2.  Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study.

Authors:  Toru Ishikawa; Michitaka Imai; Hiroteru Kamimura; Atsunori Tsuchiya; Tadayuki Togashi; Kouji Watanabe; Kei-ichi Seki; Hironobu Ohta; Toshiaki Yoshida; Tomoteru Kamimura
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

3.  Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma.

Authors:  M Mabed; L El-Helw; S Shamaa
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.